| |
Telaprevir & Boceprevir SVR - Fibrosis/Ethnicity Reported at FDA Hearing
|
| |
| |
Reported by Jules Levin
Here are several analyses presented at the FDA hearing on boceprevir & telaprevir SVR rates according to stage of fibrosis/cirrhosis and ethnicity (black/latino/Caucasian.
EASL: Boceprevir in Addition to Standard of Care Enhanced SVR in Hepatitis C Virus Genotype-1 With Advanced Fibrosis/Cirrhosis: Subgroup Analysis of SPRINT-2 and RESPOND-2 Studies
http://www.natap.org/2011/EASL/EASL_23.htm
|
|
| |
| |
|
|
|
